-+ 0.00%
-+ 0.00%
-+ 0.00%

Sumitomo Pharma America begins Phase 1/2a trial of iPS cell-derived retinal sheet therapy DSP-3077 in retinitis pigmentosa

PUBT·08/12/2026 23:34:37
Listen to the news
Sumitomo Pharma America begins Phase 1/2a trial of iPS cell-derived retinal sheet therapy DSP-3077 in retinitis pigmentosa
  • Sumitomo Pharma America dosed the first patient in a Phase 1/2a trial of DSP-3077 for non-syndromic retinitis pigmentosa.
  • No results have been presented; the study will assess safety, tolerability, engraftment, delivery performance, and early signs of benefit.
  • DSP-3077 uses an allogeneic iPS cell-derived retinal sheet delivered via a single subretinal injection in one eye.
  • Open-label, uncontrolled, dose-escalation design with 12 adults across three cohorts evaluating two dose levels.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.